NCT06749899 is a Phase 3 clinical trial of QL1706 in Nasopharyngeal Cancinoma (NPC), sponsored by Sun Yat-Sen University Cancer Center.

Who is sponsoring NCT06749899?

NCT06749899 is sponsored by Sun Yat-Sen University Cancer Center.

What drugs are being tested in NCT06749899?

Interventions in NCT06749899: QL1706, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy.

What condition does NCT06749899 study?

NCT06749899 studies Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer.

Is NCT06749899 still recruiting?

NCT06749899 is currently recruiting now. Last updated 22 May 2025.

Last reviewed 2025-05-22 · How we verify

NCT06749899

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Recruiting now Phase 3 Last updated 22 May 2025

What this trial tests

Phase 3 trial testing QL1706 in Nasopharyngeal Cancinoma (NPC) in 580 participants. Currently enrolling.

Timeline

4 May 2025

Primary endpoint
1 December 2028

1 December 2030

Quick facts

Lead sponsor	Sun Yat-Sen University Cancer Center
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	580
Start date	4 May 2025
Primary completion	1 December 2028
Estimated completion	1 December 2030
Sites	19 locations across China

Drugs / interventions tested

QL1706 — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Intensity-modulated radiotherapy

Conditions studied

Nasopharyngeal Cancinoma (NPC) — all drugs for Nasopharyngeal Cancinoma (NPC) →
Nasopharyngeal Cancer — all drugs for Nasopharyngeal Cancer →

Sponsor

Sun Yat-Sen University Cancer Center

Who can join

Adults 18 to 65, any sex, with Nasopharyngeal Cancinoma (NPC) or Nasopharyngeal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The trial aimed to compare QL1706 combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in High-risk Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Divergent immuno-landscapes: comparing the tumor microenvironment of Indian and Western HNSCC patients.
Kumar Rai P, Choudhary B. · · 2026 · PMID 42111272 · DOI 10.3389/fcell.2026.1725978

Verify or expand the search:

Other trials of QL1706

Trials testing the same drug.

NCT07530549 — A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Che · Phase 2 · not yet recruiting
NCT07413601 — Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinu · Phase 2 · not yet recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
NCT06787183 — SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases · Phase 2 · recruiting
NCT07172217 — The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC · Phase 2 · not yet recruiting

Other recruiting trials for Nasopharyngeal Cancinoma (NPC)

Currently open trials in the same condition.

NCT07362979 — Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal C · Phase 2 · recruiting
NCT07496190 — Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy · Phase 2 · recruiting
NCT07325539 — LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC · Phase 2 · recruiting
NCT07376603 — IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features · recruiting
NCT07311772 — Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid · Phase 3 · recruiting

Other Sun Yat-Sen University Cancer Center trials

Trials by the same sponsor.

NCT07288814 — Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Perip · Phase 1, PHASE2 · not yet recruiting
NCT07058428 — FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma · Phase 3 · recruiting
NCT06836505 — Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors · Phase 1, PHASE2 · recruiting
NCT06561178 — Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401) · recruiting
NCT06013618 — Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06749899 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-Sen University Cancer Center
Last refreshed: 22 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06749899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing